Skip to Content

Amitiza (lubiprostone) Disease Interactions

There are 4 disease interactions with Amitiza (lubiprostone):

Major

Lubiprostone (Includes Amitiza) ↔ GI obstruction

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Obstruction

Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Moderate

Lubiprostone (Includes Amitiza) ↔ diarrhea

Moderate Potential Hazard, Moderate plausibility. Applies to: Diarrhea, Electrolyte Abnormalities

Lubiprostone should not be prescribed to patients that have severe diarrhea. Care should be exercised when prescribing this drug to patients at risk of diarrhea and patients should be instructed to inform their physician if severe diarrhea occurs.

Moderate

Lubiprostone (Includes Amitiza) ↔ dyspnea

Moderate Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment

The use of lubiprostone may cause dyspnea. Care should be taken when prescribing this drug to patients that experienced dyspnea or when restarting the drug in those patients experiencing drug induced dyspnea.

Moderate

Lubiprostone (Includes Amitiza) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

No dosage adjustment is needed in patients with mild hepatic impairment. It is recommended to modify the dose in patients with moderate and severe hepatic impairment as these patients experienced markedly higher systemic drug exposure that can cause an increased incidence and severity of adverse events.

Amitiza (lubiprostone) drug interactions

There is 1 drug interaction with Amitiza (lubiprostone)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide